U.S. markets close in 3 hours 2 minutes
  • S&P 500

    4,592.69
    +15.58 (+0.34%)
     
  • Dow 30

    35,408.69
    +40.22 (+0.11%)
     
  • Nasdaq

    14,585.96
    +79.06 (+0.54%)
     
  • Russell 2000

    2,090.14
    -6.08 (-0.29%)
     
  • Crude Oil

    87.12
    +1.69 (+1.98%)
     
  • Gold

    1,841.60
    +29.20 (+1.61%)
     
  • Silver

    24.22
    +0.72 (+3.08%)
     
  • EUR/USD

    1.1347
    +0.0017 (+0.15%)
     
  • 10-Yr Bond

    1.8410
    -0.0240 (-1.29%)
     
  • GBP/USD

    1.3626
    +0.0028 (+0.20%)
     
  • USD/JPY

    114.3050
    -0.2800 (-0.24%)
     
  • BTC-USD

    42,162.37
    +626.21 (+1.51%)
     
  • CMC Crypto 200

    1,001.78
    +7.04 (+0.71%)
     
  • FTSE 100

    7,589.66
    +26.11 (+0.35%)
     
  • Nikkei 225

    27,467.23
    -790.02 (-2.80%)
     

Insulet to Present at Nasdaq’s 45th Investor Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ACTON, Mass., November 24, 2021--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the virtual 45th Nasdaq Investor Conference on Friday, December 3, 2021 at 11:30 a.m. (Eastern Time).

To listen to the live webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available following the event.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211124005071/en/

Contacts

Investor Relations:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Merrill Robichaud
Investor Relations Coordinator
(978) 932-0444
mrobichaud@insulet.com

Media:

Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com